Sanofi SA

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

10 May 2024 02:00:00 By Nasdaq GlobeNewswire

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

02 May 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Annual General Meeting of April 30, 2024

30 Apr 2024 12:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance

25 Apr 2024 01:30:00 By Nasdaq GlobeNewswire

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

23 Apr 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

17 Apr 2024 01:00:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - March 2024

12 Apr 2024 14:05:27 By Nasdaq GlobeNewswire

Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

08 Apr 2024 12:00:00 By Nasdaq GlobeNewswire

Press Release: Availability of the Q1 2024 Memorandum for modelling purposes

22 Mar 2024 02:30:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - February 2024

15 Mar 2024 15:04:03 By Nasdaq GlobeNewswire

Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

11 Mar 2024 02:00:00 By Nasdaq GlobeNewswire

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

24 Feb 2024 09:51:53 By Nasdaq GlobeNewswire

Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

23 Feb 2024 12:45:30 By Nasdaq GlobeNewswire

Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

23 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

22 Feb 2024 13:02:45 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - January 2024

20 Feb 2024 17:40:58 By Nasdaq GlobeNewswire

Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)

16 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS

15 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses

05 Feb 2024 02:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline

01 Feb 2024 01:30:00 By Nasdaq GlobeNewswire